Your browser doesn't support javascript.
loading
NGS-based Tissue-Blood TMB Comparison and Blood-TMB Monitoring in Stage-III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Ye, Luxi; Chu, Xiao; Ni, Jianjiao; Chu, Li; Yang, Xi; Zhu, Zhengfei.
Affiliation
  • Ye L; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Chu X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Ni J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Chu L; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Yang X; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Zhu Z; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cancer Invest ; 42(2): 165-175, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38390854
ABSTRACT
In this study, we analyzed the blood-based TMB (b-TMB) and its dynamic changes in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who received concurrent chemoradiotherapy. Baseline tissue and blood TMB from 15 patients showed a strong positive correlation (Pearson correlation = 0.937), and nearly all mutations were markedly reduced in the later course of treatment, indicating a treatment-related response. This study suggests that in patients with LA-NSCLC, b-TMB is a reliable biomarker, and its dynamic monitoring can help distinguish patients who might benefit most from the consolidated immunotherapy.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Cancer Invest Year: 2024 Type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Cancer Invest Year: 2024 Type: Article Affiliation country: China